Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$18.54 USD

18.54
3,634,555

-0.42 (-2.22%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $16.40 -2.14 (-11.54%) 4:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Adma Biologics (ADMA) Stock Moves -1.49%: What You Should Know

by Zacks Equity Research

Adma Biologics (ADMA) closed the most recent trading day at $15.84, moving -1.49% from the previous trading session.

Zacks Equity Research

Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

Adma Biologics (ADMA) closed the most recent trading day at $16.07, moving -0.62% from the previous trading session.

Zacks Equity Research

ADMA Biologics Gears Up to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On ADMA's fourth-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.

Zacks Equity Research

Adma Biologics (ADMA) Stock Moves -0.25%: What You Should Know

by Zacks Equity Research

Adma Biologics (ADMA) reachead $15.84 at the closing of the latest trading day, reflecting a -0.25% change compared to its last close.

Ekta Bagri headshot

ADMA Loses 8.9% in a Month: How Should You Play the Stock?

by Ekta Bagri

ADMA Biologics' shares lose 8.9% in a month after putting up a phenomenal performance in the past 12 months. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain.

Zacks Equity Research

Adma Biologics (ADMA) Advances But Underperforms Market: Key Facts

by Zacks Equity Research

In the closing of the recent trading day, Adma Biologics (ADMA) stood at $16.92, denoting a +0.3% change from the preceding trading day.

Zacks Equity Research

Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note

by Zacks Equity Research

Adma Biologics (ADMA) concluded the recent trading session at $16.47, signifying a +1.98% move from its prior day's close.

Zacks Equity Research

Adma Biologics (ADMA) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

Adma Biologics (ADMA) closed the most recent trading day at $16.17, moving -0.12% from the previous trading session.

Zacks Equity Research

Adma Biologics (ADMA) Rises Higher Than Market: Key Facts

by Zacks Equity Research

Adma Biologics (ADMA) concluded the recent trading session at $16.47, signifying a +1.92% move from its prior day's close.

Zacks Equity Research

Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

The latest trading day saw Adma Biologics (ADMA) settling at $16.32, representing a -1.03% change from its previous close.

Zacks Equity Research

ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock?

by Zacks Equity Research

ADMA Biologics performance in the past twelve months has been phenomenal. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain.

Zacks Equity Research

Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

Adma Biologics (ADMA) closed at $18.56 in the latest trading session, marking a +1.48% move from the prior day.

Zacks Equity Research

Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Adma Biologics (ADMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks Equity Research

Are Medical Stocks Lagging Alvotech (ALVO) This Year?

by Zacks Equity Research

Here is how Alvotech (ALVO) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Zacks Equity Research

The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex

by Zacks Equity Research

ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex are part of the Zacks top Analyst Blog.

Zacks Equity Research

4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow

by Zacks Equity Research

Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025.

Zacks Equity Research

The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam

by Zacks Equity Research

Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam are included in this Analyst Blog.

Ekta Bagri headshot

4 Biotech Stocks Most Wall Street Analysts Are Bullish About

by Ekta Bagri

Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals.

Zacks Equity Research

Are Medical Stocks Lagging ELUTIA INC (ELUT) This Year?

by Zacks Equity Research

Here is how Elutia Inc. (ELUT) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Ekta Bagri headshot

ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip?

by Ekta Bagri

ADMA Biologics has performed phenomenally in 2024. Given its strong trajectory, we recommend investors use any dip in the stock price as a buying opportunity.

Zacks Equity Research

Can Adma Biologics (ADMA) Climb 25.5% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Adma Biologics (ADMA) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Zacks Equity Research

Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and Addex Therapeutics Ltd. Sponsored ADR (ADXN) have performed compared to their sector so far this year.

Zacks Equity Research

Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

Wall Street Analysts See a 31.3% Upside in Adma Biologics (ADMA): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 31.3% in Adma Biologics (ADMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.